16 reports of this reaction
2.3% of all NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE reports
#11 most reported adverse reaction
OCULAR HYPERAEMIA is the #11 most commonly reported adverse reaction for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE, manufactured by Amneal Pharmaceuticals NY LLC. There are 16 FDA adverse event reports linking NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE to OCULAR HYPERAEMIA. This represents approximately 2.3% of all 690 adverse event reports for this drug.
Patients taking NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is a less commonly reported adverse event for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE, but still significant enough to appear in the safety profile.
In addition to ocular hyperaemia, the following adverse reactions have been reported for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 16 FDA reports for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 2.3% of all adverse event reports for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE, making it a notable side effect.
If you experience ocular hyperaemia while taking NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.